Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team

BILLERICA, Mass.--(BUSINESS WIRE)--

Insulet Corporation PODD (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod^® Insulin Management System, today announced that almost 100 members of Insulet's North American clinical team have completed a customized certification program designed and led by the Joslin Diabetes Center for Insulet. The Advanced Diabetes Educator in Pump Therapy (ADEPT™) certification provides Insulet's clinical team with customized, advanced training to deliver enhanced support for individuals who are managing their diabetes using continuous subcutaneous insulin infusion therapy. The Company's partnership with Joslin will enable Insulet's clinical team to provide unparalleled training and support for healthcare practitioners and their Omnipod patients.

Insulet is the only company to provide this advanced training and certification to its highly-credentialed clinicians. The ADEPT certification is awarded to clinical team members who successfully complete a two-day training program led by top clinicians at Joslin and who are enrolled in the ongoing Joslin educational program.

"We are proud to announce the ADEPT certification of our clinical team through our partnership with the Joslin Diabetes Center, which reflects just one of the many initiatives we are implementing to ensure we deliver the highest level of resources and support to our Podders and healthcare providers," said Shacey Petrovic, President, Insulet Diabetes Products. "In today's environment, we recognize healthcare practitioners face significant time and resource challenges. Our clinical team members help offset this burden by applying their advanced training in areas such as patient onboarding with Omnipod and advanced pattern management, becoming a true clinical partner to our customers."

Dr. Robert Gabbay, Chief Medical Officer and Senior Vice President of Joslin stated, "We are proud to partner with Insulet on this important educational initiative, which will benefit patients and clinicians alike. Consistent blood glucose control and related technology proficiency can be challenging to master, and this educational endeavor will help ensure the Omnipod clinical team will provide the advanced support needed so patients can become successful at both."

Additional information on the program will be available at the American Diabetes Association's 76^th Scientific Sessions in New Orleans, La., from June 10 to 14. Please visit Insulet's booth at location 1301 in the Morial Convention Center to learn more. The Company also plans to evaluate and share outcomes associated with the certification program in the future.

About Insulet Corporation:

Insulet Corporation PODD is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with Omnipod, please visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

About Joslin Diabetes Center:

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. Joslin develops and disseminates innovative patient therapies, educational programs and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and a federally-designated Diabetes Research Center. For more information, please visit www.joslin.org.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160610005095/en/